Intended for healthcare professionals in the UK and Ireland. Click here for Adverse Event Reporting.

Prescribing Information

Prescribing Information

 
 
 
 

PEYONA overview

 
 

PEYONA (caffeine citrate) is indicated for the treatment of primary AOP. Each 1 ml ampoule contains 20 mg caffeine citrate (equivalent to 10 mg caffeine).1

 

Treatment with caffeine citrate should be initiated under the supervision of a physician experienced in neonatal intensive care. Treatment should be administered only in a NICU in which adequate facilities are available for patient surveillance and monitoring.1

 

Mechanism of action

 
 

The mechanism of action of caffeine in AOP includes:2–4

  • Stimulation of the respiratory centre in the medulla
  • Increased sensitivity to CO2
  • Increased skeletal muscle tone
  • Enhanced diaphragmatic contractility
  • Increased minute ventilation
  • Increased metabolic rate and oxygen consumption
  • Stimulates the central nervous and cardiovascular systems
  • Enhances catecholamine secretion
  • Has a diuretic effect
  • Alters glucose homeostasis
 

PEYONA pharmaceutical form

 

PEYONA is conveniently supplied in glass ampoules with a shelf life of 3 years and does not require any special storage conditions.1

 

PEYONA is supplied as a clear, colourless, aqueous solution with a pH of 4.7 and osmolality of 144–166 mOsm/kg.1 The pH and osmolarity of PEYONA may improve IV tolerability compared with other licensed caffeine citrate preparations.5

 

Other ingredients are citric acid monohydrate, sodium citrate and water for injections.1

 
 

Abbreviations

 

AOP, apnoea of prematurity; CO2, carbon dioxide; IV, intravenous; NICU, neonatal intensive care unit.

 
 

References

  1. PEYONA (caffeine citrate) SmPC. Available at https://www.medicines.org.uk/emc/product/4098/smpc. Accessed September 2024.
  2. Comer AM, et al. Caffeine citrate: a review of its use in apnoea of prematurity. Paediatr Drugs. 2001;3:61–79.
  3. Aranda JV, et al. Pharmacologic effects of theophylline in the newborn. J Allergy Clin Immunol. 1986;78:773–780
  4. Martindale Pharma. Caffeine citrate 10 mg/mL solution for injection Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/5146/smpc. Accessed September 2024.
  5. Ejiwumi O et al. Intravenous bolus administration of caffeine citrate in premature babies. Infant 2016;12(6):219–221
 
 

IE-PEY-2400007 | December 2024

 
 

Adverse event reporting

For the UK: Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.

For Ireland: Adverse events should be reported to HPRA Pharmacovigilance – www.hpra.ie. Adverse events should also be reported to Chiesi Limited on 1800 817459 (IE) or PV.UK@Chiesi.com.